After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

Physicians recommend that patients with chronic obstructive pulmonary disease (COPD) quit smoking and use steroids, ...

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

The growing prevalence of COPD among women can be attributed to a combination of biological, environmental, and societal ...

Ensifentrine is a promising supplementary therapeutic option in the management of chronic obstructive pulmonary disease (COPD), according to systematic review and meta-analysis findings published in ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Benralizumab is more effective than prednisolone in treating eosinophilic exacerbations in patients with asthma and COPD.

Chronic obstructive pulmonary disease (COPD) market Insights: Rising prevalence of COPD due to aging and smoking.

Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...